8 February 2021 - Takeda is pleased to announce that the Scottish Medicines Consortium has accepted Prostap SR DCS & Prostap 3 DCS (leuprorelin acetate) for use in patients with early breast cancer and advanced breast cancer.

Leuprorelin acetate works by suppressing the release of luteinising hormone and follicle stimulating hormone and offers an additional treatment choice as its dosing regimen means that suitable patients with early-stage breast cancer require four clinic visits a year, up to 13 visits a year as with other GnRH agonists licensed for breast cancer.

Read Takeda press release